Search

everythinglearnresearchcommunity

for

Search:↓

Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

A 113 year old man who has more hair than most people, and the conversation is discussing potential genetic factors that may be responsible for this. Possible treatments such as dermarolling and minoxidil, finasteride, and RU58841 are mentioned.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.

A 17-year-old female is worried about hair loss, noticing thinning and bald spots. She plans to try burdock oil and castor oil, and if needed, Jamaican castor oil.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

A user shared progress pictures after 11 months on finasteride and minoxidil, with intermittent microneedling. The community responded positively, noting significant hair regrowth and encouraging continued treatment.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

A 16-year-old experiencing diffuse hair thinning is considering using minoxidil and plans to start finasteride at 18, while others suggest alternatives like saw palmetto and pumpkin seed oil. Users advise consulting a doctor before starting treatments and emphasize the importance of understanding the cause of hair loss.

Alfatradiol is often discussed at a 1% concentration, but studies typically use 0.025%. Some users report success using it as a topical treatment alongside other hair loss treatments like finasteride.

The conversation is about hair loss treatment progress using dutasteride 0.5mg and oral minoxidil 3mg. Suggestions include adding topical minoxidil with tretinoin and considering micro needling or micro stamping for further improvement.

A 23-year-old male shared his 11-month progress using 1.25mg finasteride every other day and Nizoral/Dermazole, reporting reduced hair fall and new hair growth without major shedding. Users discussed the risks of finasteride for younger individuals and suggested consulting a doctor, with some recommending minoxidil as an alternative.

A 23-year-old experiencing hair loss tried olive oil, coconut oil, and hair growth shampoos without success. They are seeking advice on whether to start treatments like Minoxidil, finasteride, or RU58841.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The conversation is about finding a source for Alfatradiol 0.1% as most available products are 0.025%. A suggestion was made to use four times the dosage of the 0.025% product.

A user shared their 11-year experience with finasteride, noting temporary increased shedding that stopped, and advised continuing the treatment despite seasonal shedding. They reported no side effects and maintained a full head of hair.

PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The user experienced hair thinning and was diagnosed with alopecia incognito and male pattern baldness. They are using minoxidil, finasteride, and dutasteride scalp injections, reporting gradual improvement with no side effects.

J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."

An 18-year-old is concerned about potential balding and seeks advice. They are unsure if their hairline is a widow's peak or if they are experiencing hair loss.

The conversation is about the availability of the PP405 formula for hair loss treatment, with mentions of finasteride and its side effects. Users discuss the potential of obtaining the formula through unofficial channels and the challenges related to its genetic sequence and delivery method.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

An 18-year-old is concerned about hair loss and seeks advice on stopping it. Treatments mentioned include Minoxidil, finasteride, and RU58841.